1] Institute for Cancer Genetics, Columbia University, New York, New York, USA. [2] Department of Pathology, Columbia University Medical Center, New York, New York, USA. [3].
1] Institute for Cancer Genetics, Columbia University, New York, New York, USA. [2].
Nat Genet. 2014 Feb;46(2):166-70. doi: 10.1038/ng.2873. Epub 2014 Jan 12.
Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non-Hodgkin lymphomas. Here we combined whole-exome sequencing of 12 tumor-normal DNA pairs, RNA sequencing analysis and targeted deep sequencing to identify new genetic alterations in PTCL transformation. These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an effect potentially mediated by the sequestration of activated guanine-exchange factor (GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.
外周 T 细胞淋巴瘤(PTCLs)是一组异质性和了解甚少的非霍奇金淋巴瘤。在这里,我们对 12 对肿瘤-正常 DNA 进行了全外显子组测序、RNA 测序分析和靶向深度测序,以鉴定 PTCL 转化中的新遗传改变。这些分析鉴定了 TET2、DNMT3A 和 IDH2 中高度复发的表观遗传因子突变,以及一种新的高度普遍的 RHOA 突变,该突变编码一种 Gly17Val 改变,存在于 35 个血管免疫母细胞性 T 细胞淋巴瘤(AITL)样本中的 22 个(67%)和 44 个非特指性外周 T 细胞淋巴瘤(PTCL-NOS)样本中的 8 个(18%)。在生化和细胞测定中,RHOA Gly17Val 蛋白通过隔离激活的鸟嘌呤交换因子(GEF)蛋白干扰 RHOA 信号,这种效应可能是由 RHOA 信号传导介导的。此外,我们还描述了新的和反复出现的遗传缺陷,尽管频率较低,但包括 FYN、ATM、B2M 和 CD58 中的突变,这表明 SRC 信号传导、DNA 损伤反应受损和逃避免疫监视机制在 PTCL 的发病机制中起作用。